STAT Inhibitors: 2018 Pipeline Insights - Analysis by Development Stage, Mechanism of Action, Route of Administration and Molecule Type -

DUBLIN--()--The "STAT Inhibitors- Pipeline Insights, 2018" report has been added to's offering.

This report outlays comprehensive insights of present scenario and growth prospects across STAT Inhibitors.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

This report provides detailed analysis of 15+ active products with more than 8 companies involved. Two of the key players include Napabucasin of Boston Biomedical and Bardoxolone methyl of Reata Pharmaceuticals.

Products covered by Phase

  • Phase III, Phase II, Phase I
  • IND
  • Pre-clinical & Discovery
  • Inactive (Dormant and Discontinued)

Overview of pipeline development activities for STAT Inhibitors

  • Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
  • Therapeutic segmentation of products for STAT Inhibitors.
  • The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.


  • Provides an overview of therapeutic pipeline activity for STAT Inhibitors across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of STAT Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across STAT Inhibitors

Key Topics Covered

  1. Executive Summary
  2. Overview
  3. Introduction
  4. Structure of STAT Protein
  5. Mechanism of Action
  6. STAT Inhibitor Mechanism
  7. Functions of STAT Proteins
  8. Diseases
  9. Pipeline Therapeutics
  10. Competitive Landscape
  11. Comparative Analysis
  12. Late Stage Products (Phase III)
  13. Comparative Analysis
  14. Napabucasin: Boston Biomedical
  15. Product Description
  16. Research and Development
  17. Product Development Activities
  18. The list continues..
  19. Mid Stage Products (Phase II)
  20. Comparative Analysis
  21. OPB-111077: Otsuka
  22. Product Description
  23. Research and Development
  24. The list continues..
  25. Early Stage Products (Phase I & IND)
  26. Comparative Analysis
  27. Pre-clinical and Discovery Products
  28. Comparative Analysis
  29. Therapeutic Assessment
  30. Assessment by Product Type
  31. Assessment by Route of Administration
  32. Assessment by Stage and Route of Administration
  33. Assessment by Molecule Type
  34. Assessment by Stage and Molecule Type
  35. Dormant and Discontinued Products
  36. Comparative Analysis
  37. Appendix

Companies Featured

  • Boston Biomedical
  • Reata Pharmaceuticals
  • Otsuka
  • GLG Pharma
  • Ionis Pharmaceuticals
  • StemMed
  • Moleculin Biotech
  • Glactone Pharma
  • Singh Biotechnology
  • Janpix Bio

For more information about this report visit

Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900